{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-001989","form_type":"8-K","ticker":"IRWD","cik":"0001446847","company_name":"IRONWOOD PHARMACEUTICALS INC","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.218809+00:00","generated_at":"2026-06-07T02:10:11.993069+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Ironwood guides FY2024 adj EBITDA >$150M, LINZESS low-single digit growth, pipeline catalysts","bullets":["Maintains FY2023 guidance: LINZESS net sales growth 6-8%, revenue $435-450M, adjusted EBITDA ~($900M) from VectivBio charge.","FY2024 guidance: LINZESS U.S. net sales low-single digit % growth, total revenue $435-455M, adjusted EBITDA >$150M.","Expects apraglutide STARS Phase 3 topline data in SBS-IF in March 2024; CNP-104 Phase 2 topline data in PBC in Q3 2024.","High-single digit LINZESS prescription demand growth in 2024 offset by mid-to-high single digit price erosion from Medicaid AMP cap removal."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-001989","json":"https://secwatch.observer/filing/0001104659-24-001989.json","markdown":"https://secwatch.observer/filing/0001104659-24-001989.md","text":"https://secwatch.observer/filing/0001104659-24-001989.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1446847/000110465924001989/0001104659-24-001989-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1446847/000110465924001989/tm242140d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:10:11.993069+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"286b51ff35f3a34c46aaaba62e8b9991ca0c7f27","claim":"IRONWOOD PHARMACEUTICALS INC reported full year 2024 results: revenue $435 - $455 million. Guidance initiated.","evidence_excerpt":"- 8% Low-single digits % High-single digit prescription demand growth offset by mid to high-single digit price erosion primarily due to Medicaid AMP cap removal Total revenue $435 - $450 million $435 - $455 million Adjusted EBITDA 1 ~($900) million Reflects ~$1.1 billion one-time charge from acquisition of VectivBio >$150 million Excludes potential","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1446847/000110465924001989/0001104659-24-001989-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2024"},{"label":"Revenue","value":"$435 - $455 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}